RIGL - RIGEL PHARMACEUTICALS INC

QQQ $ 444.59 $ 5.93 (1.35 %)

DIA $ 392.96 $ 3.39 (0.87 %)

SPY $ 527.60 $ 3.49 (0.67 %)

TLT $ 95.21 $ -0.75 (-0.78 %)

GLD $ 223.85 $ 1.12 (0.5 %)

Previous Close

$ 9.87

Open

Bid

$ 10.22 x 200

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 7.12 - $ 17.30

Volume

123,605

Average Volume

Market Cap

173.21M

Beta (5Y Monthly)

$ 1.09

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-06-2024	06-30-2024	10-Q
2	05-07-2024	03-31-2024	10-Q
3	03-05-2024	12-31-2023	10-K
4	11-07-2023	09-30-2023	10-Q
5	08-01-2023	06-30-2023	10-Q
6	05-02-2023	03-31-2023	10-Q
7	03-07-2023	12-31-2022	10-K
8	11-03-2022	09-30-2022	10-Q
9	08-02-2022	06-30-2022	10-Q
10	05-03-2022	03-31-2022	10-Q
11	03-01-2022	12-31-2021	10-K
12	11-02-2021	09-30-2021	10-Q
13	08-03-2021	06-30-2021	10-Q
14	05-05-2021	03-31-2021	10-Q
15	03-02-2021	12-31-2020	10-K
16	11-05-2020	09-30-2020	10-Q
17	08-04-2020	06-30-2020	10-Q
18	05-05-2020	03-31-2020	10-Q
19	02-27-2020	12-31-2019	10-K
20	11-05-2019	09-30-2019	10-Q
21	08-06-2019	06-30-2019	10-Q
22	05-07-2019	03-31-2019	10-Q
23	02-28-2019	12-31-2018	10-K
24	11-06-2018	09-30-2018	10-Q
25	08-08-2018	06-30-2018	10-Q
26	05-01-2018	03-31-2018	10-Q
27	03-06-2018	12-31-2017	10-K
28	11-07-2017	09-30-2017	10-Q
29	08-01-2017	06-30-2017	10-Q
30	05-02-2017	03-31-2017	10-Q
31	03-07-2017	12-31-2016	10-K
32	11-01-2016	09-30-2016	10-Q
33	08-02-2016	06-30-2016	10-Q
34	05-03-2016	03-31-2016	10-Q
35	03-08-2016	12-31-2015	10-K
36	11-03-2015	09-30-2015	10-Q
37	08-04-2015	06-30-2015	10-Q
38	05-07-2015	03-31-2015	10-Q
39	03-03-2015	12-31-2014	10-K
40	11-04-2014	09-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Rigel Pharmaceuticals shares are trading h...
08/06/2024 21:20:15

Rigel Pharmaceuticals Q2 2024 GAAP EPS $(0...
08/06/2024 20:50:10

Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of...

Trading Halt: Halted at 7:50:00 p.m. ET - ...
06/26/2024 23:50:04

Rigel Announces 1-For-10 Reverse Stock Spl...
06/25/2024 12:07:07

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it will effect a reverse stock split of its issued and outstandi...

HC Wainwright & Co. Reiterates Buy on Rige...
06/25/2024 11:22:32

HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $15...

Rigel Pharmaceuticals Completes Transfer O...
06/24/2024 20:11:39

GAVRETO will be available from Rigel in the U.S. beginning June 27, 2024SOUTH SAN FRANCISCO, Calif., June 24, 2024 /PRNewswire/...

HC Wainwright & Co. Reiterates Buy on Rige...
06/17/2024 10:18:32

HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $15...

HC Wainwright & Co. Reiterates Buy on Rige...
06/03/2024 16:34:06

HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $15...

Rigel Plans Presentations At The Upcoming ...
05/23/2024 21:15:34

Oral presentation of final five-year results from the registrational Phase 2 trial in R/R mIDH1 AML patients reinforces REZLIDH...

HC Wainwright & Co. Reiterates Buy on Rige...
05/08/2024 13:37:01

HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $15...

Rigel Pharmaceuticals Q1 2024 GAAP EPS $(0...
05/07/2024 20:40:41

Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate ...

12-health-care-stocks-moving-in-mondays-after-market-session

12 Health Care Stocks Moving In Monday's A...
04/22/2024 20:31:12

Rigel Publishes Data On REZLIDHIA In Post-...
04/04/2024 12:11:03

Olutasidenib induced durable composite complete remission in 43.8% of patients relapsed or refractory to prior venetoclax-based...

Citigroup Maintains Buy on Rigel Pharmaceu...
03/07/2024 14:30:43

Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and raises the price target fro...

Cantor Fitzgerald Maintains Neutral on Rig...
03/06/2024 17:34:17

Cantor Fitzgerald analyst Kristen Kluska maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral and raises the price t...

HC Wainwright & Co. Reiterates Buy on Rige...
03/06/2024 13:55:22

HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $15...

B. Riley Securities Maintains Neutral on R...
03/06/2024 13:37:03

B. Riley Securities analyst Kalpit Patel maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral and maintains $1.25 pr...

Rigel Pharmaceuticals: Q4 Earnings Insights
03/05/2024 21:15:05

Rigel Pharmaceuticals Q4 Sales $35.792M Be...
03/05/2024 21:14:42

Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly sales of $35.792 million which beat the analyst consensus estimate of $3...

Earnings Scheduled For March 5, 2024
03/05/2024 10:00:02

Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2...